Page 394 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 394
Fresenius Medical Care 340 K
1, Else-Kroener-Strasse
Bad Homburg, 61352
Germany
www.fmc-ag.com
Fresenius Medical Care is the world's largest integrated provider of products and services
for individuals undergoing dialysis because of chronic kidney failure, a condition that affects
more than 1,500,000 individuals worldwide. In patients suffering from severe liver failure
(like acute or “acute-on-chronic”), elimination of toxins by dialysis is not enough because
here albumin-bound toxins have to be removed too. With Prometheus®, Fresenius Medical
Care offers a therapy system that combines a procedure where a fraction of plasma is
separated from blood to remove albumin bound toxins by adsorption with hemodialysis to
clear the blood from water soluble substances.
Fujirebio Europe NV 440 A
Technologiepark
Gent, 9052
Belgium
www.fujirebio-europe.com
INDUSTRY INFORMATION Fujirebio is a leading international healthcare company specialized in high quality
IVD testing solutions. The company is world-wide leader in oncology for routine and
novel markers, has solid experience with immunoassay testing solutions and has, as
Innogenetics (now Fujirebio Europe), been pioneering the field of molecular diagnostics
and multiparameter testing. Fujirebio Europe's products in the area of infectious diseases
include INNOTEST® and INNO-LIATM assays for screening and confirmation of HIV,
HCV, HTLV and Syphilis and INNO-LiPA assays for HBV (genotyping, drug resistance
mutations, basal core/precore mutations). The LUMIPULSE® G1200 and G600II offers
fully automated screening solutions for infectious diseases (HBcrAg, …) and markers for
HCC (AFP/PIVKA-II).
Galmed Pharmaceuticals Ltd. 440 C
8, Shaul Hamelech
Tel Aviv, 6473307
Israel
www.GalmedPharma.com
We are a clinical-stage - Nasdaq traded - biopharmaceutical company focused on the
development and commercialization of a novel, once-daily, oral therapy for the treatment
of liver diseases and cholesterol gallstones utilizing our proprietary first-in-class synthetic
fatty- acid/bile-acid conjugate, or FABAC, called aramchol. We are initially developing
Aramchol for the treatment of NASH in patients who also suffer from obesity and insulin
resistance. We believe that Aramchol’s ability to reduce liver fat without observable adverse
side effects in our studies to date will enable it to be an effective treatment for NASH and
the hepatic and cardiovascular complications associated therewith.
394 The International Liver Congress™ 2015 • ILC Programme
1, Else-Kroener-Strasse
Bad Homburg, 61352
Germany
www.fmc-ag.com
Fresenius Medical Care is the world's largest integrated provider of products and services
for individuals undergoing dialysis because of chronic kidney failure, a condition that affects
more than 1,500,000 individuals worldwide. In patients suffering from severe liver failure
(like acute or “acute-on-chronic”), elimination of toxins by dialysis is not enough because
here albumin-bound toxins have to be removed too. With Prometheus®, Fresenius Medical
Care offers a therapy system that combines a procedure where a fraction of plasma is
separated from blood to remove albumin bound toxins by adsorption with hemodialysis to
clear the blood from water soluble substances.
Fujirebio Europe NV 440 A
Technologiepark
Gent, 9052
Belgium
www.fujirebio-europe.com
INDUSTRY INFORMATION Fujirebio is a leading international healthcare company specialized in high quality
IVD testing solutions. The company is world-wide leader in oncology for routine and
novel markers, has solid experience with immunoassay testing solutions and has, as
Innogenetics (now Fujirebio Europe), been pioneering the field of molecular diagnostics
and multiparameter testing. Fujirebio Europe's products in the area of infectious diseases
include INNOTEST® and INNO-LIATM assays for screening and confirmation of HIV,
HCV, HTLV and Syphilis and INNO-LiPA assays for HBV (genotyping, drug resistance
mutations, basal core/precore mutations). The LUMIPULSE® G1200 and G600II offers
fully automated screening solutions for infectious diseases (HBcrAg, …) and markers for
HCC (AFP/PIVKA-II).
Galmed Pharmaceuticals Ltd. 440 C
8, Shaul Hamelech
Tel Aviv, 6473307
Israel
www.GalmedPharma.com
We are a clinical-stage - Nasdaq traded - biopharmaceutical company focused on the
development and commercialization of a novel, once-daily, oral therapy for the treatment
of liver diseases and cholesterol gallstones utilizing our proprietary first-in-class synthetic
fatty- acid/bile-acid conjugate, or FABAC, called aramchol. We are initially developing
Aramchol for the treatment of NASH in patients who also suffer from obesity and insulin
resistance. We believe that Aramchol’s ability to reduce liver fat without observable adverse
side effects in our studies to date will enable it to be an effective treatment for NASH and
the hepatic and cardiovascular complications associated therewith.
394 The International Liver Congress™ 2015 • ILC Programme
